Proton Radiation for Chordomas and Chondrosarcomas (NCT01449149) | Clinical Trial Compass
CompletedNot Applicable
Proton Radiation for Chordomas and Chondrosarcomas
United States54 participantsStarted 2010-03
Plain-language summary
The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed diagnosis of chordoma or chondrosarcoma.
* Patients must have no evidence of metastatic disease based on routine imaging (CT or MRI of the chest/abdomen/pelvis, bone scan, etc.)
* Patients must have an ECOG score equal to or less than 2.
* Age ≥ 18 years.
* Patients must be able to provide informed consent.
* Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3
* Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.) Hysterectomy or menopause must be clinically documented.
* Tumors arising in the skull and spine.
Exclusion Criteria:
* Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
* Patients with the following histologies are excluded: melanoma , other soft tissue or bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other histologies.
* Pregnant women.
* Actively being treated on any other therapeutic research study.
* Tumors arising outside of the CNS.
What they're measuring
1
Feasibility of Proton RT for Chordomas and Chondrosarcomas
Timeframe: From enrollment to treatment completion or withdrawal, whichever occurred first, assessed up to 133 months